TRUTINO BIOSCIENCES

Trutino Biosciences is a biopharmaceutical company that develops the next generation of cytokine therapies. Trutino’s proprietary On-Demand-Cytokine (ODC) platform technology enables the design of therapeutic candidates that can be systemically delivered in an inactive cytokine form and be locally activated directly at the tumor site, thereby avoiding the extreme toxicity of conventional cytokine therapies, and potentially improving efficacy either as a single agent or in combination with other treatment modalities. The company was founded in 2017 and is based in San Diego, California.